vs
Side-by-side financial comparison of Arena Group Holdings, Inc. (AREN) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
Arena Group Holdings, Inc. is the larger business by last-quarter revenue ($28.2M vs $18.6M, roughly 1.5× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 18.9%, a 46.9% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -22.0%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -1.2%).
Arena Racing Company, also called ARC Racing and Leisure Group is a UK private company, created in 2012 by the merger of Arena Leisure and Northern Racing. It owns and operates 16 racecourses in Great Britain, accounting for 39% of British racing fixtures. It also operates hotels at Wolverhampton Racecourse, Lingfield Park Racecourse and Doncaster Racecourse and golf courses at Lingfield, Southwell and Newcastle.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
AREN vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $28.2M | $18.6M |
| Net Profit | $5.3M | $12.3M |
| Gross Margin | 43.6% | — |
| Operating Margin | 26.6% | 56.3% |
| Net Margin | 18.9% | 65.7% |
| Revenue YoY | -22.0% | 1808.5% |
| Net Profit YoY | -22.5% | 376.5% |
| EPS (diluted) | $0.12 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $28.2M | $18.6M | ||
| Q3 25 | $29.8M | $334.0K | ||
| Q2 25 | $45.0M | $1.4M | ||
| Q1 25 | $31.8M | $257.0K | ||
| Q4 24 | $36.2M | $977.0K | ||
| Q3 24 | $33.6M | $660.0K | ||
| Q2 24 | $27.2M | $736.0K | ||
| Q1 24 | $28.9M | $1.4M |
| Q4 25 | $5.3M | $12.3M | ||
| Q3 25 | $6.9M | $-8.6M | ||
| Q2 25 | $108.6M | $-6.9M | ||
| Q1 25 | $4.0M | $-5.4M | ||
| Q4 24 | $6.9M | — | ||
| Q3 24 | $4.0M | $-2.8M | ||
| Q2 24 | $-8.2M | $-14.5M | ||
| Q1 24 | $-103.4M | $411.0K |
| Q4 25 | 43.6% | — | ||
| Q3 25 | 50.2% | — | ||
| Q2 25 | 56.5% | — | ||
| Q1 25 | 49.3% | — | ||
| Q4 24 | 52.6% | — | ||
| Q3 24 | 50.6% | — | ||
| Q2 24 | 39.4% | — | ||
| Q1 24 | 30.9% | — |
| Q4 25 | 26.6% | 56.3% | ||
| Q3 25 | 31.9% | -2516.5% | ||
| Q2 25 | 36.5% | -701.0% | ||
| Q1 25 | 23.1% | -3350.2% | ||
| Q4 24 | 28.6% | — | ||
| Q3 24 | 24.0% | -1563.6% | ||
| Q2 24 | -9.5% | -1255.0% | ||
| Q1 24 | -27.5% | -692.5% |
| Q4 25 | 18.9% | 65.7% | ||
| Q3 25 | 23.1% | -2572.2% | ||
| Q2 25 | 241.4% | -504.8% | ||
| Q1 25 | 12.6% | -2097.7% | ||
| Q4 24 | 19.0% | — | ||
| Q3 24 | 11.8% | -425.5% | ||
| Q2 24 | -30.1% | -1964.4% | ||
| Q1 24 | -357.1% | 29.9% |
| Q4 25 | $0.12 | $0.25 | ||
| Q3 25 | $0.14 | $-0.17 | ||
| Q2 25 | $2.28 | $-0.14 | ||
| Q1 25 | $0.08 | $-0.11 | ||
| Q4 24 | $1.23 | — | ||
| Q3 24 | $0.11 | $-0.06 | ||
| Q2 24 | $-0.28 | $-0.30 | ||
| Q1 24 | $-3.91 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.3M | $40.0M |
| Total DebtLower is stronger | $97.6M | — |
| Stockholders' EquityBook value | $-4.8M | $49.4M |
| Total Assets | $112.6M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.3M | $40.0M | ||
| Q3 25 | $12.5M | $37.9M | ||
| Q2 25 | $6.8M | $44.8M | ||
| Q1 25 | $2.9M | $40.6M | ||
| Q4 24 | $4.4M | $59.3M | ||
| Q3 24 | $5.8M | $68.8M | ||
| Q2 24 | $6.1M | $73.0M | ||
| Q1 24 | $4.0M | $80.2M |
| Q4 25 | $97.6M | — | ||
| Q3 25 | $110.5M | — | ||
| Q2 25 | $110.5M | — | ||
| Q1 25 | $110.5M | — | ||
| Q4 24 | $110.4M | — | ||
| Q3 24 | $102.4M | — | ||
| Q2 24 | $102.4M | — | ||
| Q1 24 | $102.3M | — |
| Q4 25 | $-4.8M | $49.4M | ||
| Q3 25 | $-10.4M | $36.4M | ||
| Q2 25 | $-17.3M | $44.5M | ||
| Q1 25 | $-126.1M | $50.5M | ||
| Q4 24 | $-130.3M | $55.1M | ||
| Q3 24 | $-137.5M | $58.5M | ||
| Q2 24 | $-157.2M | $60.4M | ||
| Q1 24 | $-149.6M | $74.1M |
| Q4 25 | $112.6M | $59.0M | ||
| Q3 25 | $121.4M | $51.1M | ||
| Q2 25 | $127.8M | $60.7M | ||
| Q1 25 | $114.6M | $67.9M | ||
| Q4 24 | $116.4M | $90.6M | ||
| Q3 24 | $114.2M | $99.0M | ||
| Q2 24 | $113.4M | $107.8M | ||
| Q1 24 | $120.3M | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.1M | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 2.46× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.1M | $18.4M | ||
| Q3 25 | $12.2M | $-8.7M | ||
| Q2 25 | $10.3M | $-7.5M | ||
| Q1 25 | $3.7M | $-7.5M | ||
| Q4 24 | $-8.6M | $-24.0M | ||
| Q3 24 | $-2.3M | $765.0K | ||
| Q2 24 | $-3.2M | $-10.9M | ||
| Q1 24 | $-2.0M | $-4.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-2.4M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -7.1% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 2.46× | 1.50× | ||
| Q3 25 | 1.77× | — | ||
| Q2 25 | 0.09× | — | ||
| Q1 25 | 0.91× | — | ||
| Q4 24 | -1.25× | — | ||
| Q3 24 | -0.59× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AREN
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
